Malosa Medical is a manufacturer and supplier of single-use surgical instruments, primarily for use in the field of ophthalmology. Additional terms of the transaction were not disclosed.
“Fueled by an aging population and an increased awareness and desire for eye care globally, the ophthalmology market has and will continue to experience robust growth. Malosa’s focus on innovation, along with its vertically integrated business model – through which it owns the production process from design to distribution – uniquely positions the company to adequately serve this expanding and evolving market,” said Dana G. Mead Jr., president and CEO of BVI (Waltham, Mass).
“We are pleased to welcome Malosa employees to the BVI team and look forward to providing their comprehensive line of high-quality single-use ophthalmic instruments to a broader set of customers worldwide,” Mead said. “Malosa’s product line is highly complementary to our single-use product portfolio and we are excited to work with the company to offer customers even more options for their patients.”
With a portfolio of more than 400 products, Malosa equips surgeons with convenient, sterilized, single-use packs that contain all the instruments and consumables required for specific ophthalmic procedures. The company’s instruments are designed for use in some of the most frequently performed procedures, including cataract surgery and intravitreal injection.
BVI’s acquisition of Malosa builds on a period of significant momentum for the company, following a series of key leadership appointments made throughout the last year. Most recently, the company named Shervin Korangy, formerly a senior executive at Novartis, as chief financial officer and chief strategy officer. Other significant appointments include Mead, a former strategic advisor and partner at Kleiner Perkins Caufield & Byers (KPCB), as president and CEO.